Latest debt-to-equity ratio for Collegium Pharmaceutical: 2.59 — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow2.59
Debt-to-Equity ratio measures a company's financial leverage by comparing its total debt to shareholder equity. A lower D/E ratio generally indicates a more financially stable company with less risk.
As of the most recent data, COLL shows a debt-to-equity ratio of 2.59. That is above the Healthcare sector average of 0.93. Scroll down for historical charts and peer comparison views.
The Healthcare sector average debt-to-equity ratio is about 0.93. Collegium Pharmaceutical is at 2.59, which is higher that average. That is roughly 177.5% above the sector mean. Use the comparison chart on this page to see how COLL stacks up against individual peers as well.
Investors watch COLL's debt-to-equity ratio because it compresses price and fundamentals into one number that is easy to compare across companies and over time. Collegium Pharmaceutical's latest reading is 2.59. Combining that with growth, ROE, and debt metrics usually beats relying on a single multiple.
Besides this debt-to-equity ratio page, Stockcircle has Collegium Pharmaceutical's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect debt-to-equity ratio (currently 2.59) with ownership activity and broader fundamentals.
The Healthcare average debt-to-equity ratio is about 0.93, while COLL is at 2.59. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.